<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>简介 on Steven Shen | 沈维燕</title>
    <link>https://shen.bioinit.com/</link>
    <description>Recent content in 简介 on Steven Shen | 沈维燕</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>zh-cmn-Hans</language>
    <lastBuildDate>Mon, 12 Aug 2019 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="https://shen.bioinit.com/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>版权说明</title>
      <link>https://shen.bioinit.com/licenses/</link>
      <pubDate>Fri, 30 Aug 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/licenses/</guid>
      <description>版权：自由转载-非商用-非衍生-保持署名（知识共享署名 4.0 国际许可协议） 邮箱：ishenweiyan@qq.com 转载：原创博客请在转载时保留</description>
    </item>
    
    <item>
      <title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer</title>
      <link>https://shen.bioinit.com/research/apobec3b_signature/</link>
      <pubDate>Thu, 20 Jun 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/research/apobec3b_signature/</guid>
      <description>主要发现：APOBEC mutational signature 在 NSCLC 免疫治疗反应组内特异性富集。 摘要 Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in</description>
    </item>
    
    <item>
      <title>The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex</title>
      <link>https://shen.bioinit.com/research/tmb_diff_in_sex/</link>
      <pubDate>Thu, 20 Jun 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/research/tmb_diff_in_sex/</guid>
      <description>主要发现：NSCLC 中，TMB 对于免疫治疗反应的预测效果在不同的性别中有差异。 摘要 Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a fraction of patients show response to ICI, and there is an unmet need</description>
    </item>
    
    <item>
      <title>测试</title>
      <link>https://shen.bioinit.com/debug/</link>
      <pubDate>Thu, 30 May 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/debug/</guid>
      <description>沈维燕 测试问题记录 如果 config.toml 中 url 的名称与 content/*/index.md、content/*.md 中的 title 名称不一致，则会触发 menu 中的 item 在 active 时候</description>
    </item>
    
    <item>
      <title>简历</title>
      <link>https://shen.bioinit.com/resume/</link>
      <pubDate>Thu, 30 May 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/resume/</guid>
      <description>沈维燕 联系方式 地址：广州市黄埔区科学城科学大道182号创新大厦 邮箱：ishenwieyan@qq.com 网站：https://blog.bi</description>
    </item>
    
    <item>
      <title>简历</title>
      <link>https://shen.bioinit.com/resume/shenweiyan/</link>
      <pubDate>Thu, 30 May 2019 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/resume/shenweiyan/</guid>
      <description>沈维燕 联系方式 地址：广州市黄埔区科学城科学大道182号创新大厦 邮箱：ishenwieyan@qq.com 网站：https://blog.bi</description>
    </item>
    
    <item>
      <title>归档</title>
      <link>https://shen.bioinit.com/archives/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://shen.bioinit.com/archives/</guid>
      <description>本页面为本站点所有分类历史文章归档。具体每一个分类的文章请移步导航栏的 &amp;ldquo;文章&amp;rdquo; 页面阅读。</description>
    </item>
    
  </channel>
</rss>